/PRNewswire/ Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular.
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 .
/PRNewswire/ Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative.
Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH. | December 11, 2021
/PRNewswire/ Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative.